This audit would examine whether the Australian Nuclear Science and Technology Organisation (ANSTO) has effectively managed nuclear and related scientific assets to support Australia’s international competitiveness in scientific research, and to provide a reliable domestic supply of radiopharmaceuticals to the Australian nuclear medicine community.

ANSTO manages over $1 billion of nuclear and related scientific assets, for which it incurred over $100 million in depreciation in 2017–18. These assets include highly specialised facilities, such as the Open Pool Australian Lightwater nuclear research reactor, the Australian Synchrotron electron accelerator, and nuclear medicine production equipment. These facilities aim to advance Australia’s commercial and scientific interests by employing world-leading technology. ANSTO has identified asset management and expansion as a strategic corporate objective.